Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial

What is it about?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors help lower cardiovascular risk in people with diabetes. We studied one of these medications, empagliflozin, in patients with diabetes undergoing heart bypass surgery. In a small study, the drug appeared safe and may have helped reduce the risk of kidney injury in the first days after surgery. However, more research is needed before considering changes to how we manage diabetes before cardiac surgery.

Featured Image